Key result
Blood biomarkers including BNP and D-dimer show promise in guiding cardioembolic stroke diagnosis and prevention.
Why the study?
Many stroke patients receive a diagnosis of undetermined stroke, and biomarkers might become important tools to guide stroke etiology diagnosis and classification.
Do blood biomarkers improve the diagnosis and classification of cardioembolic stroke etiology?
Do blood biomarkers improve the diagnosis and classification of cardioembolic stroke etiology?
Blood biomarkers represent a promising diagnostic tool to identify cardioembolic stroke etiology, which could help tailor secondary prevention strategies.
May aid cardioembolic stroke classification; leaves open need for prospective validation before guiding prevention.
One promising field in neurovascular diseases investigation is the use of biomarkers to guide stroke etiology diagnosis and classification. Since treatment differs among etiologic subtypes and nowadays many patients receive a diagnosis of undetermined stroke, biomarkers might become an important additional diagnostic tool. In this review we update current knowledge about biomarkers related with cardioembolic stroke etiology (such as BNP and D-dimer proteins, or PITX2 and ZFHX3 genes), that in the future, might allow rapidly guiding other diagnostic tests and accelerating the onset of an optimal secondary prevention.
No takes yet. Share an insight, caveat, or question.
García‐Berrocoso et al. (2010) conducted a review in Cardioembolic stroke. Blood biomarkers (BNP, D-dimer, PITX2, ZFHX3) was evaluated. Blood biomarkers such as BNP, D-dimer, PITX2, and ZFHX3 show promise in guiding the etiologic diagnosis and classification of cardioembolic stroke to optimize secondary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: